
Paola Fiorani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/195569/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	From Antarctica to cancer research: a novel human DNA topoisomerase 1B inhibitor from Antarctic sponge <i>Dendrilla antarctica</i> . Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1404-1410.	5.2	5
2	Natural Compounds as Therapeutic Agents: The Case of Human Topoisomerase IB. International Journal of Molecular Sciences, 2021, 22, 4138.	4.1	14
3	In Vitro and In Silico Characterization of an Antimalarial Compound with Antitumor Activity Targeting Human DNA Topoisomerase IB. International Journal of Molecular Sciences, 2021, 22, 7455.	4.1	5
4	Topoisomerase IB: a relaxing enzyme for stressed DNA. , 2020, 3, 18-25.		7
5	Swapping of The N-Terminal Domain of Human Topoisomerase 1B with the Corresponding Counterpart Strongly Impairs Enzyme Activity. Reports of Biochemistry and Molecular Biology, 2020, 8, 366-375.	1.4	0
6	The human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance. Archives of Biochemistry and Biophysics, 2019, 663, 165-172.	3.0	1
7	Real-time analysis of cleavage and religation activity of human topoisomerase 1 based on ternary fluorescence resonance energy transfer DNA substrate. Archives of Biochemistry and Biophysics, 2018, 643, 1-6.	3.0	3
8	Mutation of Gly717Phe in human topoisomerase 1B has an effect on enzymatic function, reactivity to the camptothecin anticancer drug and on the linker domain orientation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 860-868.	2.3	11
9	Real-Time Label-Free Direct Electronic Monitoring of Topoisomerase Enzyme Binding Kinetics on Graphene. ACS Nano, 2015, 9, 11166-11176.	14.6	43
10	Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico. Molecular Cancer, 2013, 12, 100.	19.2	29
11	The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2712-2721.	2.3	14
12	Replacement of the Human Topoisomerase Linker Domain with the Plasmodial Counterpart Renders the Enzyme Camptothecin Resistant. PLoS ONE, 2013, 8, e68404.	2.5	13
13	Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin. Journal of Amino Acids, 2012, 2012, 1-8.	5.8	12
14	Interaction between natural compounds and human topoisomerase I. Biological Chemistry, 2012, 393, 1327-1340.	2.5	44
15	Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant. Nucleic Acids Research, 2009, 37, 6849-6858.	14.5	29
16	Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations. Nucleic Acids Research, 2008, 36, 5645-5651.	14.5	49
17	Effect on DNA relaxation of the single Thr718Ala mutation in human topoisomerase I: a functional and molecular dynamics study. Nucleic Acids Research, 2005, 33, 3339-3350.	14.5	47
18	Single Mutation in the Linker Domain Confers Protein Flexibility and Camptothecin Resistance to Human Topoisomerase I. Journal of Biological Chemistry, 2003, 278, 43268-43275.	3.4	81